• Recruiting

NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma

Updated: Oct 19

PERK Inhibitor

NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma

NMS-03597812

Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma


This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.


Sponsor

Nerviano Medical Sciences

 

ClinicalTrials.gov Identifier: NCT05027594


Official Title: A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple Myeloma


First Posted : August 30, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: NMS-03597812

Drug: NMS-03597812 + dexamethasone

 

PERK Inhibitor NMS-03597812


PERK Inhibitor NMS-03597812 (Code C184373)

NMS 03597812

NMS-03597812

NMS03597812

PERK Inhibitor NMS-03597812

 

Location

United States, Massachusetts

United States, New York

United States, North Carolina




Posts Archive